<div id="readability-page-1"><p>Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have received a consensus rating of &#34;Hold&#34; from the five analysts that are currently  covering the firm, Marketbeat Ratings reports. One research analyst  has rated the stock with a sell rating, one  has given a hold rating and three have issued  a buy rating on  the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $4.0167.</p><div><p><span></span><span>Get <strong>Coherus Oncology</strong> alerts:</span></p></div><p>Several equities analysts have issued reports on the company. Wall Street Zen upgraded Coherus Oncology from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th. Oppenheimer initiated coverage on Coherus Oncology in a research note on Thursday. They issued an &#34;outperform&#34; rating on the stock. Finally, Weiss Ratings  reiterated a &#34;sell (d)&#34; rating on shares of Coherus Oncology in a research report on Wednesday, October 8th.</p><p><b>View Our Latest Stock Report on CHRS</b></p><h2>Coherus Oncology Stock Down 3.0%</h2><p>Coherus Oncology stock traded down $0.05 during mid-day trading on Thursday, hitting $1.59. The company had a trading volume of 2,770,077 shares, compared to its average volume of 1,605,373. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42. Coherus Oncology has a 1 year low of $0.71 and a 1 year high of $1.89. The business has a fifty day moving average of $1.37 and a 200 day moving average of $1.32. The stock has a market cap of $192.18 million, a price-to-earnings ratio of 1.20 and a beta of 0.96. </p><p>Coherus Oncology (NASDAQ:CHRS - Get Free Report) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $11.57 million during the quarter, compared to analysts' expectations of $13.41 million.  On average, sell-side analysts expect that  Coherus Oncology will post -1.05 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Coherus Oncology</h2><p>Several hedge funds have recently added to or reduced their stakes in CHRS. Strs Ohio acquired a new position in  Coherus Oncology in the 1st quarter valued at $261,000.  Panagora Asset Management Inc. acquired a new position in  Coherus Oncology in the second quarter valued at $581,000.  International Assets Investment Management LLC purchased a new position in  Coherus Oncology during the second quarter worth about $33,000.  Corient Private Wealth LLC boosted its stake in  Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company's stock worth $44,000 after buying an additional 10,000 shares during the last quarter.  Finally, Voya Investment Management LLC acquired a new stake in  Coherus Oncology in the 3rd quarter worth about $28,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Coherus Oncology Company Profile</h2> (Get Free Report)<p>Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.  </p><p>The company's lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen's Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Coherus Oncology</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>New gold price target</li><li>Trump Planning to Use Public Law 63-43: Prepare Now</li><li>Your Bank Account Is No Longer Safe</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0hSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0hSUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Coherus Oncology Right Now?</h2><p>Before you consider Coherus Oncology, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus Oncology wasn't on the list.</p><p>While Coherus Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Coherus Oncology, Inc. (NASDAQ:CHRS) has received a consensus rating of "Hold" from five analysts. One analyst rated it as a sell, one as hold, and three as buy. The average 12-month target price is $4.0167. The stock is currently down 3.0%, trading at $1.59, with a market cap of $192.18 million. Coherus reported earnings of ($0.33) per share, beating estimates, but revenue fell short. Hedge funds hold 72.82% of the stock. Coherus specializes in biosimilar therapies for oncology.</p>

Market Beat

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

VG Health

VanEck Biotech ETF

Coherus Oncology

iShares Global Healthcare

SPDR S&P Biotech

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts